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Professional antigen-presenting cells (APCs) are re-
quired for the initiation of an immune response. 
Dendritic cells (OCs) are the most potent APCs iden-
tified thus far and can present antigen in the context 
of co-stimulatory signals required for the stimulation 
~f both primed and naive T cells. Cytotoxic T lym-
phocytes (CTLs) are critical to the immune response 
against tumors or virally infected cells. Optimal stim-
ulation of antigen-specific CTLs is the goal of evolv-
ing immunization strategies for the prevention or 
thel;"apy of viral infections and tumors. Epidermal 
dendritic cells (eOCs), or Langerhans cells, can 
present antigens for the stimulation of CD4 + T cell 
dependent anti-tuJTIor immunity and may playa role 
in tumor surveillance. The capacity of eOCs to in-
duce tumor-specific COS + CTL immunity has not 
been determined. We have previously shown that 
DCs derived from bone marrow precursors (BmOCs) 
under the influence of cytokines can induce protec-
tive, antigen-specific CTL-mediated anti-tumor im-
munity. Here we show that subcutaneous hnmuniza-
c 
ytotoxic T lymphocytes (CTLs) play an important 
role in the elimjnation of tumors and viraUy infected 
cell s (Fast and Fan. 1981 , Doherty ef ai, 1984) . T he 
induction of CTLs depends on the recognition of 
cell surC, ce pcptide-maj or histocompatibility co m-
p lex (MH C) class I complexes and the delivery of co-stimulatory 
signals by professional antigen-presenting cells (APCs). The de liv-
ery of <tn tigcn in a manncr that will fac ilitate antigen-specifi c 
stimulation of T cclls is a critical challenge in vaccine design. 
O nc approach to va ccine design is to develop strategies to deliver 
antigen via professional APCs. Dendritic cells (DCs) are the most 
po tent APCs id en tifi ed to d<tte. T hey are defin ed morpho logicall y 
by their uni quc "veiled" appearance, fun ctionally by thei.r potent 
capacity to stimulate all ofcactive T cells and their abi.li ty to prime 
n aive T cell s ill IIil/'{} lin d ill I! i'/lo (Romani e/ nl, 1989; see Steinman, 
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tion with ovalbuJTIm (OVA) peptide (SIINFEKL257_264)-
pulsed eOCs induced OVA-specific, C08+ CTLs that 
lyse the OVA-expressing target. Furthermore, mice 
vaccinated with OVA peptide-pulsed eOCs were 
completely protected from subsequent challenge b y 
the OVA-expressing melanoma MOS. The capacity o f' 
peptide-pulsed eOCs to induce CTL-mediated immu-
nity is directly dependent on the dose of eOCs ad-
ministered. Importantly, the APC capacity of eOCs is 
comparable to that of BmDCs, as mice hnmunized 
with eDC popUlations containing at least as many 
class n+/B7.2+ cells as populations of BmDCs were 
equally protected against chal1enge with MOS. These 
results demonstrate that eDCs can be potent inducers 
of antigen-specific COS+ CTL-mediated immunity. 
They suggest that eOCs may be important targets for 
antigen delivery strategies aimed at inducing anti-
viral or anti- tumor imluunity. Key words: CD8+ T 
cells/va.ccille/Laltgerha1ls cells. ] l1west Derlllatol 108:716-
720, 1997 
1991 ) , and phenotypically by their high levels of expression of 
MHC class II and co-stimulatOl), molecules including CD80 and 
CD86. The skin is rich in DCs.Epidermal DCs (eDes) , Ot 
Langerhans cells, are capable of taking up antigen in the skin , and 
then migrating to the regiona l lymph nodes whel'e th ey call 
efriciently stimulate T lymphocytes (Romani and Schuler, 1992). 
T hro ugh this " sentine l" fim ction, eDCs perform a critical immu-
noregulatory fun ction; they delivel' foreign antigens from the 
periphery to the central lymphoid organs in th e appropl~ate APC 
context for th e induction of efFector T lymphocytes . This fun ction. 
in combination with their unique access ibility, sugges ts that eD Cs 
may be important targe ts for antigen delivery strategies aimed at 
indu cin g immunity against infectious diseases and tumors. 
III 1I1tro and III 11/110 studies have demonstrated that Langerhan 
cell s can present alloantigens, protein antigens, and hap tens to 
lymphocytes (Shimizu e/ ai, 1989 ; R o mani and Schuler, 1992). 
M urine m odels suggest that eDCs are capable of inducing CD4 + T 
cell-dependent immunity to tumor-associated antigens and ma)' 
pl aya role in anti-tumor surveilhnce (Grabbe er ai , 1991; Cohen er 
al. 1994) . The capacity of e DCs to induce tumor-specific CD8"-
CTL immunity h as not been determined . 
O ur studies and others ha ve demonstrated th at BmDCs pre-
loaded with antigen and injected to a host are able to induce 
antigen-specifi c CDS + CTLs, which can m ediate both protective 
and therapeuti c immuni ty to tumors (Mayordomo e( al; 1995. 
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Ossevoort cl til, 1995; Porgador and Gilboa, 1995; Celluzzi el til, 
1996; Porgador ef til, 1996). eDCs, like DCs d erive d fr0111 bone 
ma.rrow precursors in the presence of cytokin es, d evelop dendritic 
morphology and exhibit e nhan ced surfa ce expression of MHC class 
I and II antigen and important co-stimulatory m o lecules after 2-3 d 
in c ulture (Cohen cf (/1, 1994; Razi-Wolf el ti l , 1994). T his 
"maturatio n " occurs during c ulture in the presen ce of exogenously 
added cytokines or in the presen ce of cytokines provided b y 
co - cultured keratinocytes (Luger, 1989). R ecent studies su ggest 
that different pathways of DC d evelopment exist (Caux el til, 1996; 
Peters et (//, 1996). lnterestin g ly, altho u g h DCs derived from skin 
and " matured" by co- c ulture w ith keratinocytes appear to be 
phenotypically similar to "mature" DCs derived fro m bone m arrow 
in the presen ce of exogenously added cytokines, functional com-
parisons of epithelial IJcrsl/s b o ne marrow-derived DCs h ave not yet 
been performed. In this study, we investigate dlC capacity of eDCs 
to indu ce antigen-specific CD8 + CTL-m ediate d anti-tumor immu-
niry and direc tly comp are the antigen presentation capacity of 
mature DCs derived fro m e piderm al and bone m a rrow precursors. 
M ATELUALS AND METHODS 
Mice and Cell Lines Female C57BL/6 mice 5-8 wk of age were 
purchased fro 111 The Jackson Laboratory (Bar Harbor, ME) and housed at 
the Central Animal Faci li ty of the University of Pittsburgh. RF33.70 IS a 
C57BL/6-derivcd anti-OVA + K" specifi c hybridoma described previously 
(Rock el ai, 1990b) . EL4 is a C57BLl6 T lymphoma (H-2"), and EG7 is a 
chicken egg albumin (OV A)-transfected subelone of EL4 (Moore el al. 
1988). T he M05 was constructed by tra ns tectio n of the C57BL/ 6-derived 
murine melanoma, B16 (H- 2") (ATCC, Rockville, MD). with the pAc-
neo-OV A plasmid. as described (falo e ( ai, 1995) , which encodes a 
dominant H-2 b-restricted CTL epitope (SIINfEKL). SIIN FEKL serves as 
the tmnor rejection antigen to wh.ich an immune res ponse is elicited (falo 
(( al. 1995). 
Antigen and Antibodies The peptide co rresponding to the amino acid 
sequ e nce ofOV A residues 257-264 (S IIN FEKL) (K" restricted) (Rock. C( ai, 
1990a; Falk /:1 al. 1991) was synthesized by the Peptide SyntheSis faCility of 
the University of Pittsburgh Medica) Center. Monoelonal antibodies used to 
deplete cell subsets were prepared from the hybridom<ls GK1 .S (anti-CD4. 
ATCC Till 207). 2.43 (anti-CDS , ATCC TID 210), 30-H12 (anti-Thy 1.2. 
ATCC T ID 107), B220 (a nti-B cell surti,cc glycop rotein . ATCC TID 146), 
and NK1. 1 (kindly provided by W. C hambers. University of Pittsburgh 
School of Medicine) . f luoroscein isothiocyanate-conj ugated mouse anti-
mo use I_A"'" and phycoerythrin-conjugated rat anti-mouse 137.2 monoclo-
nal antibodies (Pharmingen, San Diego, CAl were used to phenotype 
dendritic ce ll s. 
Preparation of Epidermal-Derived DCs (eDCs) D Cs were ob tained 
as described (Razi-Wolf CI ai, 1994). BrieAy, cars ftOm C5 7BL/ 6 Imce were 
separated and Aoated onto dispase (1.6 U per ~1) , Boehringer Mannheim , 
Indianapolis, IN) at 37°C. After a 1-h incubauon , epldennal sheets were 
removed and resuspended in trypsin (O .05%) / DNase (160 iLg per m l) for 15 
min at J7°C. Cell suspens ions we re obtained by d issoc iating ti ssue by 
scraping with forceps and passing it through a nylon filter (Falcon) to 
remove hair and debris. Cells were resuspended in RPMI 1640 (IOly" fetal 
bovine SerU111 , L- glu tatnine, antibiotics, 2111ercaptoethanol) , and incubated 
at 37°C (10%, CO2) for 2- 3 d (the time at which cell s reach maturity). 
Granulocyte-macrophage colony-stimulating f.,ctor (GM-CSf) was sup-
plied by keratinocytes present in the culture (Luger, 1989). Nonadhcrent 
cells were enriched over a dellSity gradient (Lymphoprep. Nycomed. 
Norway) and washed extensively before use . As determined by Aow 
cytometric analysis, approximately 35% of eDCs expressed class II MHC 
antigens (I-A +). Approximately 6-1 0';', of the eDCs expressed both CD86 
(B7.2) and class II MHC antigens (I-A +) (data not shown) . 
Preparation of Bone Marrow-Derived DCs (BmDCs) Dendritic cell s 
were prepared from bone marrow as described (Celluzzi e ( al . 1996). 
Briefly, bone marrow ce lls were depleted of lymphocytes and cultured 
overnigh t at 106 cells per ml in RPMI 1640. Cells were replated on da y 1 
at 2.5 X 10' cell s per ml with GM-CSf (lOJ U per ml; Sigma C hemica l Co., 
St. Louis , MO) and murine r1L4 (500 U pCI' ml; Sigma). Loosely adher-ent 
cells were harvested on day 8. By Aow cytometric ana lysis, 50 - 75% BmDCs 
co-expressed B7.2 and class II MI-IC (I-A +) antigens (data not shown). 
T-T Hybridoma Assay Microcultures (200 iLl/well. 96-w,, 11 Aat bottom 
plates) were prepared w ith cDCs o r BmDCs (10 5 cells/well) and Kf33.70 
(105 cells/well) in th e presence or absence of the indicated concentration of 
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peptide concentration (nc/ml) 
Figure 1. Presentation of 
exogenous peptide by epi-
dermal (eDCs) and bone 
luarrow-dcrived dendritic 
cells (BmDCs). eDCs 
(sq"ares) or BmDCs (rire/es) 
were co-cultured with the T -
cell hybridoma RF33.70 (anti-
OVA + K") (Rock C( nl. 
1990b) in the absence (opert 
S)'lf l1io/s) or presence (filled S)' I11-
bills) of OV A peptide (titrated 
as indica ted). After 18 h , su-
pe rn atants were harvested and 
assayed fot Iymphokine. Val-
ues are given as counts pe r ln in 
of dupli cate cultures. 
OVA pep tide (Fig 1). After J S h incubation ;It 3rC, lOO iLl of the 
supernatants were collected Hnd assayed for lyrnphokin e using the interI eu-
kin (1L)-2-dependent indicator ce ll line I-IT2 (Watson, 1979). The reslli ts 
are expressed as Inean counts per ITlinutc of duplicate cult.ures. Assays were 
repeated at least three ti llles. 
Cytotoxicity Assay Splenocytes (30 X 10") , harvested &om mice 7-10 d 
after the last inl111unization. were rcstit-n1.l1ated by co-culture with irradiated 
EG7 cell s (20,000 rad. 7.5 X 10") for 5 d. After this time. cytot.ox icity assays 
were performed as described (Celluzzi ", al. 1996). E ighteen hOllrs prior to 
ass"y, target cells were labeled by incubation in RPMl with "Cr (100 iLCi; 
NEN. Boston , MA) at 37°C and washed extensive ly before lISe. Nonde-
pleted or monoclonal antibody + C'-treated splenocyte effectors depleted 
for CD4 +, CDS + , T h), 1.2 +, or NK+ cells were co-cultured at 37°C in 
96-well rou nd bottol1l plates for 4 h at the indicated ratios ill RPM I with 
either 5< Cr-Iabeled OVA- expressing EG7 , or non-aVA-expressing EL4 
target cell s (2 X 10< targets/well). One hundred microliters of supernatants 
fi'om tripli ca te cultures were co ll ected and counted. Data po ints are 
expressed as the me"n percent specific release of"Cr fi'om target cells and 
were calculated as described (Rock (I ai , 1993b) . 
T -Cell Activation Assay Microcultures (5 X 10 ' - 10" cell s per we ll. 200 
).1I /well) were prepared with splenocytes from immunized or control mice 
plus irradiated OVA-expressing EG7 cells in RPM1 containing 1 % normal 
l110use scrUlll or nlcdiull1 a.lon e. in 96 well ro und-botto n1 plates and cultured 
fo r 48 h at 37°C. Sll pernat,, " ts (100 iLl) were harvested and assayed for 
Iymphokine activity on H T2 cell s as described above. The res liltS are 
expressed as m ean counts per min o f triplicate cul tures . Irradiated EG7 cell s 
a lone were included to determine background Iymphokin e stimulation 
levels (data not shown). 
Immunization and Protection Assays eDCs or BmDCs were pulsed 
for 2 h at 37 °C with SIINFEKL OVA peptide (20 ng per ml) + 
f32 -microglo bulin (132M) (10 iLg per m l, human , Sigma) (Rock c( ai, 1993a) 
in reduced senull medium (Optimem; GmCO Laboratories. Grand Island. 
NY). Ce ll s were then washed extensive ly and resuspended in phosphate-
buficred sa line (PBS) . C57BL/ 6 mice were immunized subcutaneously in 
both lower Aanks with peptide-pulsed cDCs at two concentrations ( 1 X 10" 
or 6 X 10< pcr mOllse1200 iLl at 100 iLl /side), peptide-pulsed BmDCs (6 X 
1 0"/mouseI200 iLl at 1 00 I.d / side). peptide (20 ng per ml) or PBS on day O. 
Seven dolYs hlter. mice were challenged by intraden nal injection in the 
midAanks bilaterally with MaS (5 X 10< / 1110us,,1200 iLl at 100 iLl/side) in 
PBS. T he size of the tumors was ""essed two to three t.imes weekly and 
recorded as tumor area (nll112) by m easuring the largest perpendicular 
diameters . Data an! reported as the average tumor area ± SEM an d are 
plotted until the fi rst rnousc in each test group is sacrificed. SUTv"iva l is 
recorded as the percentage of surv ivin g animals. All expedments included 
five mice per gro up and wcn: repeated . Mice becoming moribund were 
sacri ficed . All peptide pulsing was done in the presence of exogenous 
human 132M. 
RESULTS 
Exogenous Peptide Accesses Class I on the Surface of 
Cultured eDCs CTLs h ave been found to play an important role 
in the elimination of tumors. To generate CTL-mediated immu-
nity, antigen s must b e presented b y MHC class I molecul es. Access 
to this pathway is ryp ica lly limited [0 endogenou s antigen. Recent 
studies h ave sh own , h owever, that exogenously add ed p e ptide 
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Figure 2. Mice immunized with OVA peptide-pulsed epidermal-
derived dendritic cells (eDCs) prime specific T-cell responses . 
Splenocytes from immunized mice were harvested and restimulated in flasks 
or microtiter plates in the presence of irradiated EG7. (a) Supernatants from 
splenocytes stimulated 48 h in microtiter plates were assayed for lympho-
kine by culture with HT2 Ct,lls. bnmunization conditions of the mice are 
shown along the x "xis. Proliferation of HT2 cells in the presence of 
supernatant is shown for splenocytes cultured with (filled bars) or without 
(ol'ell ba,.s) irrad iated EG7 stimulators . Supern"tants from cuJture of EG? 
alone did not support HT2 proliferation (not shown). (b) Splenocytes from 
mice immunized with PBS (6 ) , OVA peptide-pulsed eDCs [6 X 10" 
cells/mouse (_), 1 X 10" cells/mouse (0 )], or OVA peptide-pulsed 
BmDCs [6 X to· cells/mouse (e)] were assayed for their ability to lyse 
5tCr_labeled OVA-expressing at the effector to target ratios shown. Results 
arc reported as percent speciflc 51 Cr release and are tbe mean of triplicate 
cultures. Less than 10% lysis was observed in non-OVA- expressing targets 
at all ratios (not shown) . 
antigen can gain access to tlus pathway by binding to class I 
molecules on the surface of APCs (Rock et ai, 1990a, Celluzzi et ai , 
1996). To assess the ability of eDCs to present functional peptide + 
Kb complexes on the cell surf.1ce, eDCs or BmDCs were cultured 
with or without the OVA peptide, SIINFEKL, in the presence of 
the OVA + Kb-specific cell hybridoma RF33.70. Cells that present 
the OVA peptide in association with its surface class I molecules 
stimulate RF3 3.70 to produce IL-2 , which is measured by prolif-
eration of the IL-2-dependel1t indicator cell lill.e, HT2. eDCs were 
able to present functional SIINFEKL + Kb complexes on the cell 
surface in the presence of exogenous peptide, at concentrations as 
low as 0.19 ng per ml, to RF33 .70 (Fig 1). Furthermore, presen-
tation of exogenous peptide by eDCs was sinular to that observed 
for BmDCs. eDCs and BmDCs cultured in the absence of peptide 
did not stimulate IL-2 production by R.F33.70 (Fig 1). 
Immunization with OVA Peptide-Pulsed eDCs Primes 
OVA-Specific T-Cell Responses To evaluate T -cell priming 
in immunized mice, we measured T-cell activity by Iymphokine 
production and lytic activity. To de ternune whether T-cell re-
sponses depended on the number of MHC class n +/ B7 .2+ cells 
used to immUluze, two doses of eDCS (1 X 10616 X 104 ) were 
compared to BmDCs (6 X 104). Flow cytometric studies showed 
that approximately 6-10% of eDCs co-expressed B7 .2 and class II 
molecules, whereas 50-75% of BmDCs were MHC class n + / 
B7.2+ (data not shown). The amount 6 X 104 was selected for 
comparison because it corresponded to the absolute number of 
BmDCs that in earlier experiments could induce antigen-specific 
CTLs (Celluzzi et ai, 1996), whereas 1 X 106 was selected to 
incorporate at least as many class lr'· /B7.2 + eDCs as BmDCs. 
To measure SIINFEKL + Kb-dependent secondat)' stimulation, 
splenocytes from mice immunized with either 6 X 104 or 1 X 10(' 
peptide-pulsed eDCs, peptide-pulsed BmDCs (6 X 104) , ' peptide 
alone, or PBS were cultured in the presence or absence of irradiated 
OVA-expressing EG7 cells, and supernatants were assayed with 
HT2 cells to determine the presence of lymphokine (Fig 2a). 
Splenocytes from mice immunized with peptide-pulsed eDCs at 
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Table I. Immunization with OVA Peptide-pulsed eDCs 
induces CDS+ CTLs 
Effector: 
Target 
1 :1 
25:1 
50:1 
% Speciflc Lysis of OVA-Expressing 
Target Cells ITol11 Splenocytes 
Nondepleted CD4- CD8- NK-
0" (0)" 0(0) 0(0) 0(0) 
28 (10) 30 (13) o (0) 29 (13) 
74 (28) 
-
, 
Thyt-
0(0) 
0(0) 
,/ Lysis observed from splenocytes harves ted frOI11 mice iml:11unized 'with I X 106 
OVA peptide-pulsed c DCs. Mea'l :!: 2%. 
b Lysis observed from spicnocyccs h:1rvcs ted frO I11 mi ce immunized with 6 X 10" 
OV A peptide-pulsed c DC,. Mean :!: 2%. 
r N ot teseed. 
1 X 106 , or BmDCs at 6 X 104 , demonstrated similar levels of 
OVA-specific activation. Neither PBS-injected control nuce nor 
mice immunized with peptide alone had measurable antigen-
specific T cell activity in this assay. Immunization with 6 X 104 
peptide-pulsed eDCs results in measurable OVA-specific activity 
tbat was signifi cantly less than tbat observed in animals immunized 
with 1 X 106 peptide-pulsed eDCs. 
OVA peptide-pulsed BmDCs induce OVA-specific CD8+ CTLs 
(Cellu zzi et ai, 1996). Effector cells obtained fi·om mice immunized 
with 6 X 104 peptide-pulsed BmDCs were able to lyse OV A-
expressing tumors (EG7, M05), but not the untransfected parents 
(EL4, BIG) (Celluzzi el ai, 1996). To evaluate and compare the 
ability of eDCs to induce OVA-specific CTLs, nuce were immu-
nized, as above , with varying numbers of eDCs pulsed with OVA 
peptide (either 6 X 104 or 1 X 106 eDCs), peptide-pulsed BmDCs 
Itt 6 X 10· cells, peptide alone, or PBS . 
III vitro restimulated spleen cells from mice immunized witll 1 X 
106 peptide-pulsed eDCs lysed the OV A-transfected EG7 cells at 
levels comparable to those fi'om mice immunized with 6 X 10~ 
peptide-pulsed BmDCs. Fu rtllermore, lysis was CD8 + T cell 
mediated (Table I) . Splenocytes depleted of CD8+ T cells were 
unable to lyse EG7 targets whereas splenocytes depleted ofCD4 or 
NK cells retained the ability to lyse EG7 targets compared to 
110ndepleted controls. Splenocytes from animals immunized with 
fewer peptide-pulsed eDCs (6 X 104 ) or PBS did not (Fig 2b) lyse 
EG7 targets at comparable levels. Spleen cells from immunized 
animals did not lyse the untransfected parent tumor, EL4 (data no! 
shown), demonstrating tbat .lysis of the tumor is antigen specific, 
depending on expression of OVA by the tumor target. 
Immunization with Peptide-Pulsed eDCs Cells Induces 
Protective Immunity to the OV A-Transfected Melanoma, 
MOS Immunization with peptide-pulsed BmDCs (6 X 104 cells) 
fully protect mice from challenge witb the OVA-transfected mel-
anoma, MOS, but not from the parent B16 (Celluzzi et ai, 1996). 
Moreover, neither BmDCs alone nor peptide alone were able to 
protect mice from tumor challenge, indicating that peptide-pulsed 
BmDCs (6 X 104 ) were necessary to prime the antigen-specific 
protective response (Celluzzi et "i, 1996). To compare the capacity 
of eDCs to BmDCs to induce protective immunity, groups of mice 
were inltTIunized, as described above, with either peptide-pulsed 
1 X 10" Or 6 X 10.1 eDCs,peptide-pulsed BmDCs, peptide alone, 
or PBS. As expected, 100% of mice immUJuzed with peptide-pulsed 
BmDCs were protected from tumor challenge (Fig 3a,b). Interest-
ingly, mice immunized with peptide-pulsed 1 X 106 eDCs were 
also completely protected, whereas 60% of mice receiving 6 X 104 
peptide-pulsed eDCs developed lethal tumors. By contrast, all mice 
receiving PBS or peptide alone developed lethal tumors. These 
results indicate that peptide-pulsed eDCs induce protective tumor 
immunity. Furthermore, they demonstrate that the etfectiveness of 
immunization depends on the number of eDCs administered. 
DISCUSSION 
T he processing and presentation of antigen that is required for 
immune responsiveness can occur through two pathways. T ypi-
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F igure 3. Immunization with a threshold level o f 
peptide-pulsed epidermal-de rived d e ndritic cells 
(eDCs) induc es protectiv e immunity to the O V A-
transfected melanoma , MOS. C57BL/6] m ice were 
imm unized wirh PBS (6 ), OVA peptide (+ ). OVA 
peptide-pul sed eDCs l6 X 10· cells/ mouse (_ ) or I X 
10" cells/ m ouse (0 )]. or OVA peptide-pul sed BmDCs 
(6 X 10" ce lls/ m ouse, . ). Seven days larer, mice were 
challenged wieh MOS. T he size (fI) of each tu m or is 
reporced as the area :t SEM in square millimeters. 
Survival (b) is recorded as ehe percentage of surviving 
anil uals. Innl1uni zation widl ullpui sed dendritic cells 
alone is nor protective (da ta not shown , C elluzzi el nl . 
1996). n = 5 fo r all experiments. 
cally , in the MHC class I pathway, intracellular or endogeno usly 
synth esized antigens, su ch as viruses , are reduced to peptides by 
pro teasomes in the cytosol. Peptides are carried by the transpo rter 
in antigen processing into the endoplasmic re ticulum where they 
form a MHC class I-peptide- 132M complex tha t is ro uted through 
the Golgi complex to the sur£1ce of the cell (Morrison ef aI, 1986 ; 
Moor.e et Ill, 1988) . Antigen synthesized w ithin the cell is recog-
nized b y MHC class I-res tricted CD 8+ CT Ls resul ting in lysis of 
the target cell . In contras t, extracellular or exogenous proteins are 
gen e r ally processed via the MHC cl ass II pathway. Peptides derived 
from extracellular pro teins in phagolysosomes outside of the cy-
tosol bind to MHC class II molecules to form MHC class ll-peptide 
complexes that can be recognized by C D4 + T helper ceUs . 
10 the eliminatio n of tumors, induction of CTLs plays an 
important role . Optimal stim ulation o f an antigen-specific CTL 
response is the aim of strategies designed for the preven tion and 
treatlnent of tumors. Although exogenous proteins are generally 
excluded from the class I presenting pathway, an approach to target 
antigen into the class I pathway is to target exogenously added 
peptides to accessible class I mo lecules on the surface of profes-
sional A PCs. APCs contain class I molecules that are accessible to 
exogen ously added peptide (Rock el Ill, 1993a, 1993b). In the 
presence of exogenously added 132M , functional complexes con-
sisting o f class I heavy chain, exogeno us peptide, and 132M are 
present on the surfaces of APC s (Rock (~ I Ill, 1993a, 1993 b) . Using 
this strategy, profess io nal APCs , which can also provide necessary 
co-stimulatory signals fo r the expansion of CTLs, were loaded ex 
vil'o w ith peptide before injection to a host. 
BmD Cs, tested in earlier studies, were able to p resen t the 
exogenously added O VA peptide, SIIN FEKL, with surface cl ass I 
molecules (Kb). SIIN FEKL-puised BmDCs inj ected subcutaneously 
induced antigen-specific, CD 8 + CTL-mediated pro tec tive immu-
nity to M05, an O VA- transfected , C57BL/6 mouse-derived , B1 6 
melanoma. In the current studies, we used the sam e B1 6/M05 
mode l to compare the ability o f eD Cs and BmDCs to presen t 
exogen o usly added peptide to an MHC cl ass I-res tricted hybrid and 
to induce antigen-specific CTL-medi ated immunity. 
Manlra tion and development of cultured D Cs is mediated by 
exogenously added GM-CSF or GM-CSF produced by kera tino-
cytes present in cultul'e (Heufler el Ill, 1988; Luger, 1989; lnaba el 
ai, 1992). In o ur studies BmDCs w ere cultured in the presence of 
both G M-CSF and IL-4 (Sallusto and Lanzavecchia , 1994) whereas 
eDes were grown in the presence of keratinocytes that provide a 
source of cytokines including GM-CS F (Luger, 1989). It is also 
irnportant to consider that both 'eD C and BmDC preparations are 
hetero genous cell populations that contain cell types o ther than 
dendritic ceUs. N onetheless, BmDCs and eD Cs in our studies 
resembled each other m orphologically, phenotypically. and fun c-
nonally. 
III v itro studies demons trate that even w hen small amounts of 
exogenous SIINFEKL peptide w as added «1 ng per ml) to eD Cs, 
functional OVA + Kh complexes fo rmed on the cell surface, at 
levels s imilar to BmDCs (Fig 1), indicating that these cells have 
compar able levels of MHC class I m olecules tha t are accessible to 
exogenously added peptides . 
Furthermo re, OVA peptide-pulsed eD Cs induce OVA-specific 
T -cell immunity (Fig 2a, II). T he effectiveness of this fo rm of 
immunization depends on the number of peptide-pulsed eDCs used 
to immunize. Splenocytes harvested ti-om mice immunized with 
eDCs adjusted to incl ude at least as many APCs as in the Bm DCs 
preparation (1 X 106 eDCs = 1 X 105 class ll + / B7.2+ cells). show 
similar levels o f OV A-speci6c activation and lytic activ ity. Lim ited 
tar get lysis is observed from mice immunized with fewe r (6 X 104 ) 
peptide-pulsed eDCs (6 X 10" = 6 X 103 class n + /B7.2 + cells). 
Mice immunized widl peptide alone did not produce sign ifican t 
responses in either assay (Fig 2) . 
Bo th cytolytic ac tivity and Iymp hokine responses correlated with 
ill 1';1/0 p rotec tion. All mice (1000A,) immunized w ith 1 X 106 
peptide-p ulsed eDCs or 6 X 104 peptide-pulsed Bm DCs were 
pro tec ted from tumo r challenge (Fig 311,/1) . By contrast, 40% of 
mice immunized wi th fewer (6 X 10~ ) peptide-pulsed eDCs were 
pro tected . T he partial protection observed in this group , coupled 
w ith the intermedia te Iympho kine productio n and CTL activity 
observed , suggests tha t this number of eDCs may be on dl e 
threshold between an effective and ineffective imm unizing dose. 
O ur resul ts, using de fin ed antigens, support previous studies that 
dem onstrate tha t epidermal Lan gerhans cells pulsed with tumor 
Iysates stimulate protective tumor immunity (Grabbe ct Il l. 1991; 
Cohen el aI, 1994) and demo nstrate the induction of an tigen-
speci6c CT Ls . 
Peptide loading on to DCs might offer several advantages over 
the administration of free peptide or <m tigen . Because the peptide is 
presented o n a complex on die cell surface, the peptide avoids 
degrada tion by extracelluIar proteases (Falo el Il l . 1992). In addi-
tion, no free peptide is available to bind no nprofessiona.l APCs. Free 
peptide administered alone could target healthy cells for destruc-
tion , or bind to uonprofessional APCs . w hich lacking co-stimula-
tory m olecu les , may result in down regulation rather d1an stimula-
tion. 
Immunogenicity of dendritic cells depends presumably 0 11 a 
number of fac tors including (i) the effectiveness of antigen loading, 
(ii) the delive ry of co-stimula to ry signals and (iii) tra fficking of 
antigen-loaded cells on readministration. It is likely that several 
variables, including the origin of the dendritic cells, their culture 
conditions, which affect the expression/ regulation of relevant 
co-stimulatory molecules, thei r routes of adm inistration , and their 
dose , w ill affec t irnmunogenicity. 
W e have previo usly shown that i ll Il i l/'o culture conditions used to 
generate BmDCs can efrect their immunogenicity ill IiiI/O (Mayor-
dom o el aI, 1995) . T he studies repo rted here directly compare the 
immwlOgenicity of eD Cs w ith BmDCs. T hey demonstrate that like 
BmDCs, peptide-pulsed eDCs can induce antigen-specific CD8 + 
CTLs and tumor immuni ty if similar numbers of class 11 + IB7 .2+ 
cells are present. T hus, eDCs appea red functionall y similar to 
BmDCs in our experiments. We have recentl y reported that 
deli very of an tigen-encoding genes to cutaneous DCs i ll l,il'IJ resul ts 
in the induction of po tent an tigen-specifiC CTL-m ediated imm u-
nity (Condon el Ill , 1996). T aken together. these studies p rovide 
rationale fo r the development of immunization stra tegies d1at ta rget 
an tigen delivery to cutaneous DCs ill lIitro or ill lI il' ll. 
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